Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US

That is the title of a paper published today in Future Oncology with co-authors Erin Mulvey, Kyi-Sin Than, Sanjana Muthukrishnan, Alex Mutebi, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, Diala Harb, Victor Gonzalez, Sarah Quinlan, Vardhaman Patel and Patrick Connor Johnson. The study was conducted in collaboration with the Lymphoma Research Foundation. The abstract is below:…

Read More

Limitados por políticas de Trump, los registros de cáncer solo reconocerán a pacientes como “hombre” o “mujer”

Las máximas autoridades en estadísticas del cáncer de Estados Unidos pronto deberán clasificar el sexo de los pacientes estrictamente como hombre, mujer o desconocido, un cambio que, según científicos y defensores de pacientes, afectará negativamente la salud de la población transgénero, una de las más marginadas del país. Médicos y activistas por los derechos de…

Read More

Are drug prices value-based?

One of the central tensions in pharmaceutical policy is the gap between what a drug is worth and what it actually costs. In theory, a drug’s price should reflect its value — its ability to improve health outcomes relative to the next best alternative. In practice, list prices are set by manufacturers, net prices are shaped by opaque…

Read More